Get started
MERCK & CO., INCMERCK & CO., INCMERCK & CO., INC

MERCK & CO., INC

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

MRK trade ideas

Merck&Co Analysis 05.10.2021Hello Traders, welcome to this free and educational analysis. I am going to explain where I think this asset is going to go over the next days/weeks and where I would look for trading opportunities. If you have any questions or suggestions which asset I should analyse tomorrow, please leave a comment below. I would also appreciate, if you would smash that like button and help me to create more free analysis like that. Thank you for watching and I will see you tomorrow!
NYSE:MRK
by basictradingtv
1
Merck is Flying based on the biased perception..!Merck data shows Molnupiravir will decrease mortality and hospitalization which is a good news, but do not forget it does not mean you do not need COVID-19 Vaccine..! This is only for those who becomes positive for COVID test, while Vaccine is for everyone! While many people debate about their choice of being vaccinated or not, I would like to show other countries example: Australia: No Jab No Pay is an Australian policy initiative which withholds three state payments – Child Care Benefit, the Child Care Rebate and a portion of the fortnightly Family Tax Benefit part A per child – for parents of children under 20 years of age who are not fully immunized or on a recognized catch-up schedule. No Jab No Play is a related policy that disallows unvaccinated children from attending preschool and childcare centres, and imposes fines on childcare centres that admit unvaccinated children. The system allows exemptions for children who cannot be safely vaccinated for medical reasons. As a doctor I respect patients choice, but when it is about public health things will become a little complicated from ethical point of view! I got vaccinated as soon as it becomes possible, and asked all my family members to do so. I want to use this opportunity to ask you to get vaccinated and do not pay attention to misinformation. I published short analysis on MRNA before this news: Best, Moshkelgosha
NYSE:MRKShort
by Moshkelgosha
2
$MRK - that fake out!!This is a perfect example of the manipulation that can occur in the market. They intentionally sold this down below the trend line and massive consolidation since beginning of 2020. It was done right before a massive announcement. It shows the importance of being invested in quality, buying at the right price, and holding through until you find fundamental reasons not to. Trading is dangerous because the technicians and algos know how to mess you up. GLL!!!
NYSE:MRK
by UnknownUnicorn16739272
MERCK GOOD OPPORTUNITY Merck & Co., Inc., d.b.a. Merck Sharp & Dohme outside the United States and Canada, is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668. Merck & Co. was established as an American affiliate in 1891 Entry on the bullish break of the dynamic trendine or on exceeding the weekly maximum. Excellent operation with a risk / return ratio of 1.20
NYSE:MRKLong
by UnknownUnicorn25541012
MRK Testing the upper limits But Can It Make New Highs?MRK is back in this 382-236 fib range with both lining up pretty tightly with the current levels on the chart. 382 is a bit looser and more of a pivot area, for now, that's been a magnet for the stock over the last few weeks. Meanwhile, 236 was tested a few times and MRK was rejected each time. With the last update on Keytruda, it's going to be interesting to see what comes next. "Merck’s (NYSE:MRK) big news on July 27th marked a watershed moment for the company’s cancer treatment, Keytruda. The Food & Drug Administration approved Keytruda for treating patients with high-risk early-stage triple-negative breast cancer (TNBC), in combination with chemotherapy. Following surgery, Keytruda could then continue as a single agent adjuvant. This approval was based on Merck’s Phase 3 KEYNOTE-522 trial....Merck’s (NYSE: MRK) blockbuster drug, Keytruda, and Bristol-Myers’ YERVOY treatments target the same checkpoint inhibitors that are part of the B7 family (PD-1/PD-L1 and CTLA-4/CD80). They’ve also both demonstrated a clear survival benefit when it comes to immune-oncology treatment...This B7H3 protein is a checkpoint molecule, which has very recently become a target for cancer treatment." Quote Source & Read More: Hot Biotech Stocks To Watch After Sanofi’s Acquisition Of Translate Bio
NYSE:MRK
by PennyStocks101
MRK GREAT FUNDAMENTAL LONG ,We have a bounce with strenght on the MA 2000, prce looking to fell up the previous GAP. Price moving due to earnings, we looking for a big raise in next months. Price target between $100- $102 ( SV LeeRink / Truist Securities / JP Morgan) BIG funds Buying this stock, : - Warren Buffett - Berkshire Hathaway Add 28.10% -Mark Hillman - Hillman Fund Add 54.95% -Lee Ainslie - Maverick Capital Add 161.78% Important note: ⚠️ All trades have risks that the investor must consider before investing. VivirdelTrading.club makes a disclaimer of any operation that may generate losses. All information transmitted by the channel, the page and the alert system is shared in good faith. There is no guarantee of 100% of the executed operations, as these are based on statistical models and assumptions regarding the past behavior of the price of a share, but they do not guarantee the same future behavior.
NYSE:MRKLong
by Vivir_Del_Trading